利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

99 条记录 (耗时 0.037 秒)

    Contrast agents
    5.
    发明授权
    Contrast agents 失效
    对比剂

    公开(公告)号：US06783752B2

    公开(公告)日：2004-08-31

    申请号：US10007325

    申请日：2001-12-05

    申请人： Jonny Østensen ,  Morten Eriksen ,  Sigmund Frigstad ,  Pål Rongved

    发明人： Jonny Østensen ,  Morten Eriksen ,  Sigmund Frigstad ,  Pål Rongved

    IPC分类号： A61B800

    CPC分类号： A61K49/223 ,  Y10S977/928 ,  Y10S977/929

    摘要： Ultrasonic visualisation of a suject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations include a coadministerable composition comprising a diffusible component capable of inward diffusion into the dispersed gas phase to promote temporary growth thereof. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences in return signal intensity from normal and hypoperfused myocardial tissue respectively.

    摘要翻译： 使用新型含气体的造影剂制剂进行超声波可视化，特别是心肌和其他组织中的灌注，其可在给药后在体内促进气相的可控和临时生长，因此可用作沉积灌注示踪剂。 制剂包括可共混组合物，其包含能够向内扩散到分散气相中以促进其暂时生长的可扩散组分。 在心脏灌注成像中，制剂可以有利地与血管扩张剂药物如腺苷共同施用，以分别增强来自正常和低灌注心肌组织的返回信号强度的差异。

    Fullerene (C60) -based X-ray contrast agent for diagnostic imaging
    9.
    发明申请
    Fullerene (C60) -based X-ray contrast agent for diagnostic imaging 有权
    富勒烯（C60）为基础的X线造影剂进行诊断成像

    公开(公告)号：US20020164288A1

    公开(公告)日：2002-11-07

    申请号：US10038075

    申请日：2001-11-09

    发明人： Lon J. Wilson ,  John T. Wharton ,  Uri Sagman

    IPC分类号： A61K049/04

    CPC分类号： B82Y15/00 ,  A61K47/6949 ,  A61K49/0447 ,  B82Y5/00 ,  Y10S516/901 ,  Y10S977/835 ,  Y10S977/928

    摘要： An contrast agent for therapeutic or diagnostic treatment comprises a fullerene scaffold and an iodinated moiety bonded to the scaffold. The agent may further comprise a water solubilizing moiety bonded to the scaffold, which may be a serinol malonodiamide, hydroxyl, and 1,3-diol. The fullerene scaffold may comprise an empty fullerene or an endohedral fullerene. A method for making the agent includes a) synthesizing iodinating moieties, b) protecting serinols, forming protected serinols, c) attaching the protected serinols to the iodinated moieties, forming iodinated serinols, d) attaching the iodinated serinols to the fullerene scaffold, and, optionally, d) de-protecting the serinols. Also disclosed are a method for providing diagnostic treatment to a patient comprising administering to said patient a radiopaque effective amount of a contrast agent comprising a fullerene scaffold and an iodinated moiety, a method of making a blood pool agent.

    摘要翻译： 用于治疗或诊断治疗的造影剂包括富勒烯支架和结合到支架的碘化部分。 该试剂还可以包含结合到支架上的水溶性部分，其可以是丝氨醇壬二酰胺，羟基和1,3-二醇。 富勒烯支架可以包括空的富勒烯或内嵌的富勒烯。 制备该试剂的方法包括：a）合成碘化部分，b）保护丝氨醇，形成受保护的丝氨醇，c）将被保护的丝氨醇连接到碘化部分，形成碘化丝氨醇，d）将碘化丝氨醇连接到富勒烯支架上， 任选地，d）脱保护丝氨醇。 还公开了一种向患者提供诊断治疗的方法，包括向所述患者施用不透射线的有效量的包含富勒烯支架和碘化部分的造影剂，制备血液池剂的方法。

    Diagnostic imaging of lymph structures
    10.
    发明授权
    Diagnostic imaging of lymph structures 失效
    淋巴结构的诊断成像

    公开(公告)号：US06444192B1

    公开(公告)日：2002-09-03

    申请号：US09245828

    申请日：1999-02-05

    申请人： Robert F. Mattrey

    发明人： Robert F. Mattrey

    IPC分类号： A61B800

    CPC分类号： A61K49/223 ,  A61K49/225 ,  Y10S977/928 ,  Y10S977/929

    摘要： In accordance with the present invention, there are provided methods for identifying the sentinel lymph node in a drainage field for a tissue or organ in a subject. In select embodiments, the invention allows for the identification of the first or sentinel lymph node that drains the tissue or organ, particularly those tissues associated with neoplastic or infectious diseases and disorders, and within the pertinent lymph drainage basin. Once the drainage basin from the tissue or organ, i.e., the sentinel lymph node, is identified, a pre-operative or intraoperative mapping of the affected lymphatic structure can be carried out with a contrast agent. Identification of the first or sentinel lymph node, on the most direct drainage pathway in the drainage field, can be accomplished by a variety of imaging techniques, including ultrasound, MRI, CT, nuclear and others. Moreover, once the lymphatic structure is identified as being associated with neoplastic or infectious diseases and disorders, the affected lymphatic structure can be removed surgically or by a suitable minimally invasive procedure to allow pathological analysis to be performed to determine whether certain diseases or disorders exist, without resort to more radical lymphadenectomy. Further, the agent can be made to carry diagnostic or therapeutic probes to be activated and/or delivered to the injection site or any part of the lymphatic pathway downstream from the injection site.

    摘要翻译： 根据本发明，提供了用于鉴定受试者中组织或器官的排水区域中的前哨淋巴结的方法。 在选择的实施方案中，本发明允许鉴定排出组织或器官的第一或前哨淋巴结，特别是与肿瘤或感染性疾病和病症相关的那些组织以及相关的淋巴引流盆内。 一旦从组织或器官即前哨淋巴结中排出流域，就可以用造影剂进行受影响的淋巴结构的术前或术中的映射。 在排水领域最直接的排水路径上识别第一个或前哨淋巴结，可以通过各种成像技术，包括超声，MRI，CT，核等等来实现。 此外，一旦淋巴结构被鉴定为与肿瘤或感染性疾病和病症相关，则可以通过手术或通过合适的微创手术来移除受影响的淋巴结构，以允许进行病理分析以确定是否存在某些疾病或病症， 而不需要更根本的淋巴结清扫术。 此外，可以使试剂携带要被激活和/或递送至注射部位的下游的注射部位或淋巴管道的任何部分的诊断或治疗探针。